EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis

Jean-Paul Makhzoum, Maria C Cid, Maxime Samson, Joerg Henes, Verena Schönau, Georgina Espigol-Frigole, Carolyn Ross, Mark A Ahlman, Ming-Chun Hsu, Shu Li, Pauline Verdijk, Linda Okonkwo und 2 weitere

Annals of the Rheumatic Diseases · 2026

DOI: 10.1016/j.ard.2026.01.009 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Jean-Paul Makhzoum und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Vasculitis Clinic, Hopital Sacré-Coeur de Montréal, University of Montreal, Montreal, QC, Canada. Electronic address: …. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Global Services LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Guselkumab, a monoclonal antibody, selectively targets the p19 subunit of interleukin-23. This randomised, double-blind, placebo-controlled, phase 2 study evaluated guselkumab vs placebo for the treatment of giant cell arteritis (GCA). METHODS: Patients ≥50 years of age with new-onset or relapsing GCA were randomised 2:1 to guselkumab or placebo. Both arms received background glucocorticoid (GC) therapy, with a protocol-defined taper through week 26. The primary endpoint was the proportion of patients achieving GC-free remission at week 28. RESULTS: Thirty-five patients were randomised to receive guselkumab and 18 to receive placebo. All patients were White, 70% were female, and the mean age was 71.5 years; 60% had new-onset and 40% had relapsing GCA. At week 28, 40% (14/35) and 33% (6/18) of patients in the guselkumab and placebo groups, respectively, achieved GC-free remission (P = .64), whereas 31% (11/35) and 39% (7/18) had experienced a GCA flare or discontinued due to worsening GCA. Median time to first GCA flare through week 28 was not estimable (NE) in the guselkumab group (90% CI: 27.7-NE) and 29.7 weeks (90% CI: 20.1-NE) in the placebo group (P = .64). Through week 60, 97% (34/35) and 94% (17/18) of patients in the guselkumab and placebo groups, respectively, had adverse events (AEs); the most common AEs, aside from worsening of GCA (49% and 56%, respectively), were COVID-19 infection (23% and 28%) and headache (17% and 39%). CONCLUSIONS: The study's primary endpoint (GC-free remission) was not met; results do not support the use of guselkumab in the treatment of GCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Giant Cell ArteritisAntibodies, Monoclonal, HumanizedHumansFemaleAgedDouble-Blind MethodMiddle AgedRecurrenceMaleGlucocorticoidsTreatment OutcomeAged, 80 and overRemission Induction

Substanzen

Antibodies, Monoclonal, HumanizedguselkumabGlucocorticoids

Autor:innen und Institutionen

  • Division of Internal Medicine, Vasculitis Clinic, Hopital Sacré-Coeur de Montréal, University of Montreal, Montreal, QC, Canada. Electronic address: jean-paul.makhzoum@umontreal.ca.
  • Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Department of Internal Medicine and Clinical Immunology, Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases, Dijon-Bourgogne University Hospital, University EPE Bourgogne Europe, Dijon, France.
  • Department of Internal Medicine II (Hematology, Oncology, Clinical Immunology, and Rheumatology), University Hospital Tuebingen, Tuebingen, Germany.
  • Department of Medicine 3, Rheumatology and Immunology, Friedrich-Alexander Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum fur Immuntherapie (DZI) Freidrich-Alexander-Univers…
  • Division of Internal Medicine, Vasculitis Clinic, Hopital Sacré-Coeur de Montréal, University of Montreal, Montreal, QC, Canada.

Förderung

  • Janssen Global Services LLC

Zitieren

APA

Makhzoum, J. P., Cid, M. C., Samson, M., Henes, J., Schönau, V., Espigol-Frigole, G., Ross, C., Ahlman, M. A., Hsu, M. C., Li, S., Verdijk, P., Okonkwo, L., Grayson, P. C., & Blockmans, D. (2026). A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.01.009

Vancouver

Makhzoum JP, Cid MC, Samson M, Henes J, Schönau V, Espigol-Frigole G, et al. A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.01.009

BibTeX
@article{Makhzoum2026,
  author = {Makhzoum, Jean-Paul and Cid, Maria C and Samson, Maxime and Henes, Joerg and Schönau, Verena and Espigol-Frigole, Georgina and Ross, Carolyn and Ahlman, Mark A and Hsu, Ming-Chun and Li, Shu and Verdijk, Pauline and Okonkwo, Linda and Grayson, Peter C and Blockmans, Daniel},
  title = {A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2026.01.009}
}
Kostenlos starten →